| Bioactivity | EGFR-IN-132 (Compound 23) is an inhibitor for EGFR, that inhibits the EGFR wildtype, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S mutans with IC50 of 1.6, 0.025, 0.019, 0.022, and 0.029 nM. EGFR-IN-132 exhibits good pharmacokinetics characteristics with high oral exposure[1]. |
| CAS | 2809982-20-3 |
| Formula | C27H31N7O3 |
| Molar Mass | 501.58 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Liu F, et al., Macrocyclic compound containing benzoheterocycle and acting as egfr kinase inhibitor, and pharmaceutical composition and use thereof. WO2022166741 |
EGFR-IN-132
CAS: 2809982-20-3 F: C27H31N7O3 W: 501.58
EGFR-IN-132 (Compound 23) is an inhibitor for EGFR, that inhibits the EGFR wildtype, L858R/T790M, d19/T790M, L858R/T790M
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.